51638-90-5 Usage
Uses
Used in Pharmaceutical Industry:
16-phenoxy tetranor Prostaglandin F2α methyl ester is used as a therapeutic agent for modulating luteolysis, a process essential for the regulation of the estrous cycle and menstrual cycle in mammals. Its high affinity for the FP receptor makes it a potent candidate for treating conditions related to the reproductive system.
Additionally, due to its smooth muscle contraction properties, 16-phenoxy tetranor Prostaglandin F2α methyl ester is used as a treatment option for glaucoma, a condition characterized by increased intraocular pressure. By promoting smooth muscle contraction, it helps to facilitate the outflow of aqueous humor, thereby reducing intraocular pressure and potentially preventing optic nerve damage and vision loss.
Used in Research Applications:
In the field of scientific research, 16-phenoxy tetranor Prostaglandin F2α methyl ester serves as a valuable tool for studying the mechanisms of action and signaling pathways associated with the FP receptor. Its stable and lipophilic nature makes it an ideal compound for investigating the role of PGF2α and its analogs in various biological processes, including reproductive physiology, smooth muscle function, and potential therapeutic applications in other areas.
Check Digit Verification of cas no
The CAS Registry Mumber 51638-90-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,6,3 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 51638-90:
(7*5)+(6*1)+(5*6)+(4*3)+(3*8)+(2*9)+(1*0)=125
125 % 10 = 5
So 51638-90-5 is a valid CAS Registry Number.
51638-90-5Relevant academic research and scientific papers
Wang, Yili,Wos, John A.,Dirr, Michelle J.,Soper, David L.,DeLong, Mitchell A.,Mieling, Glen E.,De, Biswanath,Amburgey, Jack S.,Suchanek, Eric G.,Taylor, Cynthia J.
, p. 945 - 952 (2000)
The in vitro evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is described. These compounds are potent and selective ligands for the human prostaglandin F receptor (hFP receptor). The compounds lack the olefin unsaturation required for potency in the natural ligand PGF(2α) yet retain binding affinity for the hFP receptor in the nanomolar to micromolar range. Removal of the alkenes also results in a better selectivity ratio for the hFP receptor over the other prostaglandin receptors tested. A rationale for the selectivity differences of various analogues, based on ligand docking experiments to a putative hFP receptor model, is also described.
